Global Pharmaceutical Quality Summit amplifies conversations on making quality pharmaceuticals in India, sustainably, for the world

Previous story:

Three students from the Oakridge International School Bachupally gain access to the best universities in the world

Global Pharmaceutical Quality Summit amplifies conversations on making quality pharmaceuticals in India, sustainably, for the world

Posted on February 27, 2022

The second day of the IPA’s Pharmaceutical Quality Summit brought together global leaders and regulators from across industries, highlighting the importance of a “quality mindset” as a “culture” for be ready for the future

New Delhi : The two-day Global Pharmaceutical Quality Summit 2022 organized by the Indian Pharmaceutical Alliance (IPA) successfully concluded last night. The event saw industry captains and ecosystem regulators deliberate on achieving excellence and quality in operations, vaccine development and sustainability. We also saw leaders from across industries share their insights on innovation, technology and potential learnings for the pharmaceutical industry.

The highlight of the day was the panel discussion on “End-to-End Sustainable Operations and Quality Excellence – The Way Forward” which brought together the CEOs of India’s leading pharmaceutical companies such as Cipla, Dr Reddy’s, Lupin, Sun Pharma, Torrent and Zydus. This session was moderated by Gautam Kumra, Senior Partner, McKinsey & Company.

Echoing his perspective on new modalities such as biosimilars, Mr. Umang Vohra, CEO of Cipla, said, “We have developed our technologies in-house for generics and now we need to collaborate with those who have it. already done, then build on it. The talent required for certain technologies is not present in India, so working with global partners will help solve this problem.

Speaking on the challenges of the digitalization journey, Mr. GV Prasad, co-chairman of Dr. Reddy’s, said“Although digitization is inevitable, digitization remains a challenge because the underlying processes must be mastered and understood to improve the efficiency of the digitization process. Industry leaders will need to be more agile, make decisions about data-driven leadership with science and common sense combined.

Elaborating on the crystallization of his vision for quality, Mr. Nilesh Gupta, Managing Director of Lupin, said, “Quality and compliance used to be a very company-specific issue, and that has changed thanks to forums like this one. these, which allowed us to work towards a collective. goal. Information sharing has been a huge support system. We are known for being Pharmacie du Monde and we are lucky to have achieved this position. Over the next 5 years, it will be great to be recognized as the best in class with the help of forums like this that foster open dialogue. »

Addressing the severe supply chain shock during COVID-19, Mr. Dilip Shanghvi, General Manager of Sun Pharmaceutical, spoke about building resilience. “Creating options is important to have a backup. Government LIP programs help create a self-sustaining supply chain and have contributed to efficient procurement during the pandemic. Still, there is a long way to go and we will gradually close the gap,” he said.

Talk about the biggest trends in operations and quality in the industry, Mr. Pankaj Patel, President, Zydus Lifesciences said,”COVID-19 has brought a focus on technology, automation and ushered in our digital entry into manufacturing and supply chain. Even on the API front, new manufacturing technologies have emerged and l entry into the biosimilar market can be considered.

The panel then discussed environmental, social and corporate governance.

Earlier, in a special address, Dr. Rogério Gaspar, Director of the Department of Regulation and Prequalification of WHO, spoke about “the future of pharmaceutical operations and quality”. The panel discussion on “Vaccine Development: From Concept to Delivery in Vaccine Manufacturing” was addressed by Dr. Nivedita Gupta, Scientist F and Head of Virology Unit, ICMR and saw the participation of Dr. Kapil Maithal, President, Vaccines and Diagnostics, Zydus and Dr. Sanjay Singh, CEO, Gennova Biopharmaceuticals. This was moderated by Mr. Shirish Belapure, Senior Technical Advisor, IPA. Another panel discussion focused on “Quality Excellence in Industries and Potential Learnings for Pharmaceuticals” which was addressed by Mr. Adil Zainulbhai, Chairman of Quality Council of India and saw the participation of Dr. Ranjana Pathak, President, Global Quality, Medical Affairs and Pharmacovigilance, Cipla, Mr. Nandkumar Kulkarni, Senior Director, Integrated Supply Chain, Mondelez and Mr. Vijay Kalra, Director, Mahindra Institute of Quality and Chairman, Central Safety Council for Mahindra Group. Mr. Naveen Unni, Partner, McKinsey & Company led a session on “Sustainability in Operations”.

The final session of the event was on the “DnA Roadshow of Latest Technological Advances in Pharmaceutical Quality and Operations” which saw the participation of Dr. Rajesh Kuppuswamy, Health Science Industry Advisor, SAP, Ms. Lalitha Surabhi, Associate Vice President, Strategy and Business Development, Caliber and Mr. Samuel Samson, Head, Pharmaceuticals and life sciences vertical, Siemens. This was moderated by Dr Navneet Tewatia, Associate Secretary General, IPA. The event ended with closing remarks from Mr. Nilesh Gupta and a vote of thanks from Mr. Shirish Belapure.